Anidulafungin

Intravenous
Oesophageal candidiasis

Intravenous
Invasive candidiasis, Candidaemia, Candida infections (intra-abdominal abscess, pertonitis)

No dosage adjustment needed.

No dosage adjustment needed.

Reconstitute each 50 mg vial w/ sterile water for inj 15 mL, or each 100 mg vial w/ sterile water for inj 30 mL to provide a concentration of 3.33 mg/mL. Further dilute the reconstituted solution w/ either dextrose inj 5% or sodium chloride inj 0.9% to obtain a solution containing 0.77 mg/mL.

Y-site administration: Sodium bicarbonate, ertapenem.

Hypersensitivity to anidulafungin or other echinocandins.

Patients w/ serious underlying conditions receiving multiple concomitant medications w/ anidulafungin may experience hepatic abnormalities e.g. hepatitis, hepatic dysfunction or worsening hepatic failure. Pregnancy and lactation.

Infusion-related reactions (e.g. pruritus, urticaria, rash, hypotension, dyspnoea, flushing); nausea, diarrhoea; phlebitis/thrombophlebitis, neutropaenia, hypokalaemia, headache; elevated alkaline phosphatase, hepatic enzymes, and γ-glutamyltransferase.

IV: C

Monitor liver function test.

Description: Anidulafungin is a semi-synthetic echinocandin antifungal. It inhibits 1, 3-β-D-glucan synthesis, an essential component of the fungal cell walls. It has been shown to have in vitro activity against many Aspergillus spp and Candida spp.
Pharmacokinetics:
Distribution: Volume of distribution: 30-50 L. Plasma protein binding: >99%.
Metabolism: Undergoes slow chemical degradation to an open-ring peptide lacking antifungal activity. Not hepatically metabolised.
Excretion: Via faeces: <10% (as unchanged drug); urine: <1%. Terminal elimination half-life: 40-50 hr.

Reconstituted solution: Store up to 1 hr between 2-8°C prior to reconstitution. Infusion solution: Store between 2-8°C and should be administered w/in 24 hr. Do not freeze.

Antifungals